You are here

Study Finds Few Medicare Limits on Prescription Opioids

While restrictions are increasing, a third of plans impose none

Medicare plans place few restrictions on the coverage of prescription opioids, despite federal guidelines recommending such restrictions, a new Yale study finds. The research results highlight an untapped opportunity for Medicare formularies to limit opioid prescribing, the researchers said.

The risk of opioid overdoses rises when individuals are prescribed opiates at high dosages. While the Centers for Disease Control and Prevention (CDC) issued new guidelines for prescribing opioids in 2016, little is known about opioid coverage and restrictions under Medicare, which often serves as the standard for other insurers.

For its observational study, the Yale team reviewed prescription drug plan formulary files from the Centers for Medicare and Medicaid Services in 2006, 2011, and 2015. The researchers included data from Medicare Advantage and Part D plans, examining coverage for all opioid medications except methadone.

The researchers found that in 2015, one-third of the drugs were prescribed with no restrictions, such as prior authorization or step therapy. That is down from two-thirds unrestricted in 2006, but still a significant portion had no prescribing limitations, said the study’s first author, Elizabeth Samuels, MD, MPH, a postdoctoral fellow in the National Clinical Scholars Program.

While limits in the quantities of pills prescribed did increase over time, the type of dosage restrictions recommended by the CDC accounted for only 13% of prescriptions covered in 2015, the researchers noted.

The study also found a modest increase in coverage of opiates between 2006 and 2015. “An increasing number of opiates were added to the formulary list,” Samuels noted.

Prescribing restrictions can have an impact, the researchers said. A prior study of a private insurer reported a 15% decrease in opioid prescribing when the insurer implemented restrictions, including prior authorization, quantity limits, and provider–patient agreements.

Samuels adds that several states have passed legislation to enact prescribing limitations using formularies. “People are looking for any way to control the increase in opioid-use disorder. This is one strategy,” she said.

The findings are published in the Annals of Internal Medicine.

Source: Yale University; October 9, 2017.

More Headlines

Conversely, Kids Who Need Drugs Go Untreated
May Reduce the Need for Open-Heart Surgery
NDEA, a Known Carcinogen, Discovered During FDA Testing
Cleared for Adults with Relapsed or Refractory Disease
Approved as Maintenance Treatment for Opioid Dependence
Says Company’s OxyContin Had “Significant Role” in Opioid Epidemic
Study Uses Experimental Software to Decode Variations in Mood
Mixup with Losartan Discovered in Bottles